Board to review standalone Q2 and half-year results on 12 November 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.5 pts more than Nifty Microcap 250 and 2.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board will meet on 12 November 2026 to consider standalone unaudited results for the quarter and half year ended 30 September 2026. The filing provides no financial figures. The window for insiders to trade the company's securities is closed from 1 October 2026 until the close of trading hours on 16 November 2026.
Results are still pending, so no earnings trend can be confirmed. The main near-term stock-price risk is the market reaction to the results announcement.
The filed figures for this quarter have not reached us in XBRL yet, so there is nothing to compute here; the read above is the AI's, from the document. The table appears the moment the figures land.